#METABOLOMICS WORKBENCH michaelsa93_20170829_140850_mwtab.txt DATATRACK_ID:1229 STUDY_ID:ST000872 ANALYSIS_ID:AN001405 PROJECT_ID:PR000604 VERSION 1 CREATED_ON September 6, 2017, 8:52 am #PROJECT PR:PROJECT_TITLE Maternal Hypoxemia and oxidative stress in the fetus, newborn, and adult. PR:PROJECT_SUMMARY Gestational hypoxia presents a significant stress to an unborn fetus that can PR:PROJECT_SUMMARY lead to significant complications related to fetal growth restriction and PR:PROJECT_SUMMARY resulting in diseases in the newborn as well as those manifesting later in life. PR:PROJECT_SUMMARY Recent evidence indicates that inflammation and oxidative stress are PR:PROJECT_SUMMARY contributing factors to hypoxia-related diseases. The Center for Perinatal PR:PROJECT_SUMMARY Biology at Loma Linda University has studied gestational chronic hypoxia in a PR:PROJECT_SUMMARY sheep model for over 20 years to study dysfunction of vascular and nonvascular PR:PROJECT_SUMMARY tissues derived from mothers, fetuses and offspring. In this project we are PR:PROJECT_SUMMARY attempting to use metabolomics to assess metabolic dysregulation in vascular PR:PROJECT_SUMMARY tissues along with markers of oxidative stress and inflammation in the mother PR:PROJECT_SUMMARY and offspring to determine the extent of dysregulation due to chronic hypoxia. PR:PROJECT_SUMMARY Untargeted metabolomics analysis focused on sheep plasma and arteries from the PR:PROJECT_SUMMARY lung, resistance arteries in the brain, uterine arteries, and cultured human PR:PROJECT_SUMMARY myocytes will be used to explore markers of glucose and lipid metabolism PR:PROJECT_SUMMARY disruption. Targeted analyses of oxylipins and endocannabinoids will be used on PR:PROJECT_SUMMARY the same samples to explore markers of oxidative stress and inflammation, which PR:PROJECT_SUMMARY should be increased during hypoxia. This study should delineate pathways and PR:PROJECT_SUMMARY biomarkers that help explain how hypoxia leads to the development of neonatal as PR:PROJECT_SUMMARY well as adult-onset diseases associated with chronic hypoxia that are PR:PROJECT_SUMMARY inter-related with fetal growth restriction. PR:INSTITUTE University of California, Davis PR:DEPARTMENT Genome and Biomedical Sciences Facility PR:LABORATORY WCMC Metabolomics Core PR:LAST_NAME Fiehn PR:FIRST_NAME Oliver PR:ADDRESS 1315 Genome and Biomedical Sciences Facility, 451 Health Sciences Drive, Davis, PR:ADDRESS CA 95616 PR:EMAIL ofiehn@ucdavis.edu PR:PHONE (530) 754-8258 PR:FUNDING_SOURCE NIH U24DK097154 #STUDY ST:STUDY_TITLE Maternal Hypoxemia and oxidative stress in the fetus, newborn, and adult. ST:STUDY_TITLE exercise training for peripheral artery disease ST:STUDY_TYPE Disease model ST:STUDY_SUMMARY Gestational hypoxia presents a significant stress to an unborn fetus that can ST:STUDY_SUMMARY lead to significant complications related to fetal growth restriction and ST:STUDY_SUMMARY resulting in diseases in the newborn as well as those manifesting later in life. ST:STUDY_SUMMARY Recent evidence indicates that inflammation and oxidative stress are ST:STUDY_SUMMARY contributing factors to hypoxia-related diseases. The Center for Perinatal ST:STUDY_SUMMARY Biology at Loma Linda University has studied gestational chronic hypoxia in a ST:STUDY_SUMMARY sheep model for over 20 years to study dysfunction of vascular and nonvascular ST:STUDY_SUMMARY tissues derived from mothers, fetuses and offspring. In this project we are ST:STUDY_SUMMARY attempting to use metabolomics to assess metabolic dysregulation in vascular ST:STUDY_SUMMARY tissues along with markers of oxidative stress and inflammation in the mother ST:STUDY_SUMMARY and offspring to determine the extent of dysregulation due to chronic hypoxia. ST:STUDY_SUMMARY Untargeted metabolomics analysis focused on sheep plasma and arteries from the ST:STUDY_SUMMARY lung, resistance arteries in the brain, uterine arteries, and cultured human ST:STUDY_SUMMARY myocytes will be used to explore markers of glucose and lipid metabolism ST:STUDY_SUMMARY disruption. Targeted analyses of oxylipins and endocannabinoids will be used on ST:STUDY_SUMMARY the same samples to explore markers of oxidative stress and inflammation, which ST:STUDY_SUMMARY should be increased during hypoxia. This study should delineate pathways and ST:STUDY_SUMMARY biomarkers that help explain how hypoxia leads to the development of neonatal as ST:STUDY_SUMMARY well as adult-onset diseases associated with chronic hypoxia that are ST:STUDY_SUMMARY inter-related with fetal growth restriction. ST:INSTITUTE USDA ST:DEPARTMENT Obesity and metabolism research unit ST:LABORATORY Newman's Lab ST:LAST_NAME Newman ST:FIRST_NAME John ST:ADDRESS 430 West Health Sciences Dr. Davis, Ca, 95616 ST:EMAIL John.Newman@ars.usda.gov ST:PHONE (530) 752-1009 #SUBJECT SU:SUBJECT_TYPE Sheep SU:SUBJECT_SPECIES Ovis aries SU:TAXONOMY_ID 9940 SU:GENDER Both #SUBJECT_SAMPLE_FACTORS: SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data SUBJECT_SAMPLE_FACTORS - A10 Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - B04 Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - C10 Life stage:Adult | Pregnancy status:Pregnant | Treatment group:Normoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - B05 Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - B02 Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - E03 Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - G09 Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - E05 Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - C05 Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - D05 Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - B07 Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - C03 Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - H04 Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - F01 Life stage:Adult | Pregnancy status:Pregnant | Treatment group:Hypoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - F04 Life stage:Adult | Pregnancy status:Pregnant | Treatment group:Hypoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - B01 Life stage:Adult | Pregnancy status:Pregnant | Treatment group:Hypoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - G08 Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - E04 Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - E01 Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - F05 Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - C07 Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - E10 Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - H02 Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - A07 Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Arterial SUBJECT_SAMPLE_FACTORS - A04 Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Arterial SUBJECT_SAMPLE_FACTORS - D09 Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Arterial SUBJECT_SAMPLE_FACTORS - H08 Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Arterial SUBJECT_SAMPLE_FACTORS - F08 Life stage:Adult | Pregnancy status:Pregnant | Treatment group:Hypoxic | Sample origin:Arterial SUBJECT_SAMPLE_FACTORS - A09 Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Arterial SUBJECT_SAMPLE_FACTORS - G04 Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Arterial SUBJECT_SAMPLE_FACTORS - A01 Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Arterial SUBJECT_SAMPLE_FACTORS - E08 Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Arterial SUBJECT_SAMPLE_FACTORS - C02 Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Arterial SUBJECT_SAMPLE_FACTORS - E09 Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Arterial SUBJECT_SAMPLE_FACTORS - C06 Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Arterial SUBJECT_SAMPLE_FACTORS - G07 Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Arterial SUBJECT_SAMPLE_FACTORS - (D06 + H01) / 2 Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - (A02 + H09) / 2 Life stage:Adult | Pregnancy status:Pregnant | Treatment group:Normoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - G03 Life stage:Newborn | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - B08 Life stage:Newborn | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - H06 Life stage:Newborn | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - H07 Life stage:Newborn | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - B09 Life stage:Newborn | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - A06 Life stage:Newborn | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - B03 Life stage:Fetus | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - E02 Life stage:Fetus | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - G05 Life stage:Fetus | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - G01 Life stage:Fetus | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - D02 Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - A03 Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - A05 Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - G02 Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - F10 Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Venous SUBJECT_SAMPLE_FACTORS - F02 Life stage:Fetus | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Arterial SUBJECT_SAMPLE_FACTORS - E06 Life stage:Fetus | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Arterial SUBJECT_SAMPLE_FACTORS - H05 Life stage:Fetus | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Arterial SUBJECT_SAMPLE_FACTORS - D01 Life stage:Fetus | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Arterial SUBJECT_SAMPLE_FACTORS - D08 Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial SUBJECT_SAMPLE_FACTORS - D07 Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial SUBJECT_SAMPLE_FACTORS - C08 Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial SUBJECT_SAMPLE_FACTORS - C09 Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial SUBJECT_SAMPLE_FACTORS - E07 Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial SUBJECT_SAMPLE_FACTORS - D04 Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial SUBJECT_SAMPLE_FACTORS - C04 Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial SUBJECT_SAMPLE_FACTORS - F07 Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial SUBJECT_SAMPLE_FACTORS - (D03 + F09) / 2 Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial #COLLECTION CO:COLLECTION_SUMMARY Whole blood was immediately separated by centrifugation and the plasma frozen in CO:COLLECTION_SUMMARY liquid nitrogen and stored at -80C for later analysis. CO:SAMPLE_TYPE Blood CO:BLOOD_SERUM_OR_PLASMA Venous and arterial plasma #TREATMENT TR:TREATMENT_SUMMARY To induce chronic hypoxia, pregnant and non-pregnant ewes were transported to TR:TREATMENT_SUMMARY the White Mountain Research Station that is owned and operated by the University TR:TREATMENT_SUMMARY of California. Animals were housed at the Barcroft Research Station (3800 m) for TR:TREATMENT_SUMMARY 100+ days prior to having the pregnant or non-pregnant ewes or 2 week old TR:TREATMENT_SUMMARY newborn lambs transported back to Loma Linda for study. #SAMPLEPREP SP:SAMPLEPREP_SUMMARY After randomization, a 50 μl plasma aliquot in a 1.5 mL polypropylene Eppendorf SP:SAMPLEPREP_SUMMARY tube was enriched with deuterated surrogates in 10 µL methanol (Tables S1 and SP:SAMPLEPREP_SUMMARY S2 from Agrawal, K., L.A. Hassoun, N. Foolad, T.L. Pedersen, R.K. Sivamani, J.W. SP:SAMPLEPREP_SUMMARY Newman. 2017. Sweat lipid mediator profiling: a non-invasive approach for SP:SAMPLEPREP_SUMMARY cutaneous research. J. Lipid Res. 58:188–195 [EPub: Nov 7, 2016]. doi: SP:SAMPLEPREP_SUMMARY 10.1194/jlr.M071738) and 5 μl of BHT/EDTA in 1:1 methanol/water (v/v). A total SP:SAMPLEPREP_SUMMARY of 200 μl 1-cyclohexyl uredio, 3-dodecanoic acid / 1-phenyl ureido, 3-hexanoic SP:SAMPLEPREP_SUMMARY acid (CUDA / PUHA) in 1:1 methanol/acetonitrile (v/v) was added, the sample SP:SAMPLEPREP_SUMMARY mixed by vortexing and protein precipitate was removed by centrifugation (10 SP:SAMPLEPREP_SUMMARY min, 10,000 RCF, 6 °C). The supernatant was filtered by centrifugation through SP:SAMPLEPREP_SUMMARY 1 µm PVDF membranes (Millipore, Billerica, MA) at 6 °C and 4,500 RCF for 3 SP:SAMPLEPREP_SUMMARY min. The filtrate was stored in glass vials at -20 °C until UPLC-MS/MS SP:SAMPLEPREP_SUMMARY analysis. #CHROMATOGRAPHY CH:CHROMATOGRAPHY_TYPE Reversed phase CH:INSTRUMENT_NAME Waters Acquity CH:COLUMN_NAME Aquity C18 BEH 1.7µm 100mm x 2.1mm column CH:FLOW_GRADIENT See protocol/methods file CH:FLOW_RATE 0.25 mL/min CH:COLUMN_TEMPERATURE 60 °C CH:SOLVENT_A 0.1% acetic acid CH:SOLVENT_B 90% ACN / 10% IPA CH:INTERNAL_STANDARD See protocol/methods file CH:RETENTION_TIME See protocol/methods file CH:SAMPLE_INJECTION 5 µL CH:ANALYTICAL_TIME 20 min CH:WEAK_WASH_SOLVENT_NAME 20% methanol, 10% isopropanol CH:WEAK_WASH_VOLUME 600 µL CH:STRONG_WASH_SOLVENT_NAME 50:50 Acetonitrile:Methanol CH:STRONG_WASH_VOLUME 600 µL #ANALYSIS AN:ANALYSIS_TYPE MS #MS MS:MS_COMMENTS - MS:INSTRUMENT_NAME ABI Sciex 6500 QTrap MS:INSTRUMENT_TYPE Triple quadrupole MS:MS_TYPE ESI MS:ION_MODE POSITIVE #MS_METABOLITE_DATA MS_METABOLITE_DATA:UNITS Concentration (nM) MS_METABOLITE_DATA_START Samples A09 D09 H08 A01 C02 C06 E08 E09 G04 G07 F08 B07 C03 C05 C07 D05 (D06 + H01) / 2 E04 G08 E01 E10 F05 H02 H04 B01 F01 F04 A04 A07 A10 B02 B04 B05 E03 E05 G09 (A02 + H09) / 2 C10 C04 C08 C09 (D03 + F09) / 2 D04 D07 D08 E07 F07 A03 A05 D02 F10 G02 D01 E06 F02 H05 B03 E02 G01 G05 A06 B09 H07 B08 G03 H06 Factors Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Arterial Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Arterial Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Arterial Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Arterial Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Arterial Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Arterial Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Arterial Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Arterial Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Arterial Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Arterial Life stage:Adult | Pregnancy status:Pregnant | Treatment group:Hypoxic | Sample origin:Arterial Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Venous Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Venous Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Venous Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Venous Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Venous Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Venous Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Venous Life stage:Adult | Pregnancy status:Unknown | Treatment group:Hypoxic | Sample origin:Venous Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Venous Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Venous Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Venous Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Venous Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Hypoxic | Sample origin:Venous Life stage:Adult | Pregnancy status:Pregnant | Treatment group:Hypoxic | Sample origin:Venous Life stage:Adult | Pregnancy status:Pregnant | Treatment group:Hypoxic | Sample origin:Venous Life stage:Adult | Pregnancy status:Pregnant | Treatment group:Hypoxic | Sample origin:Venous Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Arterial Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Arterial Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Venous Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Venous Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Venous Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Venous Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Venous Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Venous Life stage:Adult | Pregnancy status:Non-pregnant | Treatment group:Normoxic | Sample origin:Venous Life stage:Adult | Pregnancy status:Pregnant | Treatment group:Normoxic | Sample origin:Venous Life stage:Adult | Pregnancy status:Pregnant | Treatment group:Normoxic | Sample origin:Venous Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Arterial Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Venous Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Venous Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Venous Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Venous Life stage:Fetus | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Venous Life stage:Fetus | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Arterial Life stage:Fetus | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Arterial Life stage:Fetus | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Arterial Life stage:Fetus | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Arterial Life stage:Fetus | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Venous Life stage:Fetus | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Venous Life stage:Fetus | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Venous Life stage:Fetus | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Venous Life stage:Newborn | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Venous Life stage:Newborn | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Venous Life stage:Newborn | Pregnancy status:- | Treatment group:Hypoxic | Sample origin:Venous Life stage:Newborn | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Venous Life stage:Newborn | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Venous Life stage:Newborn | Pregnancy status:- | Treatment group:Normoxic | Sample origin:Venous PEA 99.2 76.7 94.9 136 69.1 78.9 48.7 110 60.2 51 62.9 67.8 75.9 60.7 52.3 74.1 79.35 42.3 66.9 68.8 89 58.3 75.9 54.7 119 85.9 78.3 112 86.7 88.5 69.9 81.4 81.1 46 46.2 65.3 94.85 64.8 98.6 57.9 72.9 78.75 96.4 80 69.4 56.8 69 143 107 87.5 75.7 131 72.7 63.9 51.3 98.8 90.4 62 68.2 62.7 106 42.7 88.6 64.6 82.5 59.9 SEA 117 89.5 108 274 106 90.1 82.3 147 58.3 91 97.4 151 138 101 87.4 108 117.5 92.9 67.3 95.3 126 87.5 144 106 247 129 85.1 191 158 164 127 164 164 134 75 92.3 159.5 66.9 89.8 61.3 94 94 126 103 51.7 72.5 83.2 168 132 103 84.9 176 103 73.8 57.1 119 161 86.1 79.1 64.6 223 82.6 134 128 144 102 OEA 2.77 2.4 2.44 2.82 1.55 1.56 1.27 1.09 1.99 0.997 1.86 4.99 1.6 2.73 1.72 2.19 2.795 1.59 1.98 1.25 1.12 1.79 2.51 2.12 4.66 1.61 1.54 2.37 1.28 2.18 1.85 2.03 2.86 11 1.13 1.77 3.06 3.85 1.17 0.825 0.972 0.91 1.04 1.43 0.735 0.918 0.963 0.888 1.17 0.696 1.2 1.75 1.8 2.03 1.95 2 2.38 1.66 1.9 1.39 2.34 2.26 1.99 5.19 2.75 5.34 LEA 0.307 0.315 0.368 0.343 0.273 0.364 0.203 0.168 0.339 0.214 0.449 0.448 0.288 0.481 0.243 0.387 0.869 0.252 0.39 0.239 0.261 0.326 0.448 0.289 0.588 0.384 0.352 0.27 0.0958 0.31 0.189 0.238 0.271 0.701 0.228 0.308 0.473 0.546 0.0686 0.0396 0.0394 0.0245 0.0291 0.0651 0.0268 0.0399 0.0379 0.0418 0.0299 0.0378 0.0771 0.0876 0.0606 0.0956 0.0711 0.0444 0.0726 0.0694 0.0673 0.0609 0.466 0.528 0.437 0.552 0.506 0.877 aLEA 0.0383 0.0583 0.042 0.039 0.0569 0.0466 0.0348 0.0184 0.0378 0.0311 0.0336 0.0511 0.0278 0.056 0.0253 0.064 0.06805 0.0454 0.0513 0.0325 0.0327 0.0492 0.0718 0.0233 0.0434 0.0335 0.0355 0.104 0.0453 0.114 0.0619 0.0537 0.101 0.0925 0.0766 0.138 0.1023 0.233 0.00552 0.00153 ND 0.00839 0.00259 0.00309 0.00316 0.0061 0.00267 0.00493 0.00559 0.0035 0.00136 0.0122 0.00942 0.00943 0.0142 0.00938 0.00995 0.0143 0.0107 0.0221 0.0599 0.0852 0.0502 0.281 0.163 0.291 DGLEA 0.0212 0.022 0.0418 0.0373 0.0487 0.0355 0.00976 0.0233 0.03 0.0374 0.0637 0.0953 0.057 0.0643 0.0291 0.0551 0.07855 0.106 0.0686 0.0391 0.024 0.0517 0.0562 0.0358 0.12 0.0282 0.0343 0.0109 0.0186 0.0769 0.0451 0.0294 0.0132 0.0686 0.00895 0.0294 0.0537 0.00655 0.0064 0.00512 0.000311 0.01735 ND 0.00208 0.00704 0.0104 0.00983 0.00308 0.0123 0.0121 0.00707 0.0142 0.00753 0.0182 0.0159 0.00863 0.0312 0.0164 0.00639 0.000124 0.0373 0.0641 0.0173 0.033 0.0555 0.0249 AEA 0.109 0.164 0.0943 0.0825 0.115 0.0852 0.0386 0.0429 0.0767 0.0514 0.107 0.0799 0.064 0.135 0.0659 0.166 0.2505 0.0888 0.0992 0.0618 0.0658 0.104 0.114 0.0755 0.204 0.142 0.098 0.0763 0.0479 0.0973 0.0473 0.0412 0.082 0.185 0.0684 0.0729 0.176 0.105 0.0985 0.056 0.0403 0.0468 0.00438 0.0896 0.0555 0.0226 0.0307 0.0315 0.0297 0.0263 0.0417 0.0868 0.0583 0.053 0.0927 0.0633 0.0744 0.0615 0.0659 0.0432 0.0887 0.0814 0.0458 0.0743 0.0795 0.0945 DEA 0.255 0.329 0.366 0.417 0.37 0.403 0.2 0.151 0.549 0.372 0.43 0.247 0.387 0.59 0.294 0.223 0.746 0.351 0.277 0.217 0.216 0.489 0.166 0.446 0.73 0.418 0.485 0.171 0.149 0.287 0.228 0.0965 0.438 0.558 0.123 0.194 0.2135 0.409 0.475 0.293 0.274 0.2025 0.3 0.612 0.489 0.225 0.443 0.489 0.26 0.13 0.34 0.725 0.512 0.382 0.0744 0.382 0.2 0.382 0.274 0.0308 0.691 0.819 1.26 0.488 0.641 0.327 DHEA 0.117 0.192 0.142 0.166 0.207 0.18 0.125 0.0828 0.106 0.134 0.15 0.196 0.107 0.173 0.138 0.257 0.2335 0.248 0.169 0.228 0.226 0.293 0.257 0.0681 0.259 0.154 0.117 0.147 0.136 0.138 0.225 0.172 0.245 0.14 0.167 0.222 0.1865 0.193 0.138 0.182 0.0864 0.136 0.119 0.314 0.119 0.1 0.122 0.213 0.109 0.168 0.0879 0.199 0.263 0.245 0.31 0.239 0.214 0.333 0.196 0.179 0.233 0.229 0.195 0.465 0.733 0.538 NO-Gly 7.75 6.38 4.94 3.28 1.53 2.33 1.99 1.24 4.01 1.95 5.65 6.03 5.64 8.28 3.3 7.05 8.44 3.94 6.15 2.28 1.78 3.59 4.73 4.39 6.64 2.33 2.91 5.17 2.57 8.93 3.35 3.39 7.48 4.67 6.07 6.19 9.475 15.1 0.907 0.521 0.476 1.585 1.13 2.77 0.57 1.4 1.5 1.16 0.686 0.864 1.32 1.51 1.16 1.78 1.9 1.5 1.8 2.03 1.16 1.48 2.9 3.44 3.04 2.26 2.82 2.59 NA-Gly 0.169 0.123 0.231 0.195 0.0823 0.17 0.0868 0.0606 0.212 0.1 0.332 0.252 0.124 0.333 0.0605 0.234 0.1755 0.123 0.205 0.14 0.104 0.0506 0.135 0.11 0.215 0.0966 0.089 0.157 0.0393 0.22 0.148 0.0484 0.351 0.0207 0.134 0.233 0.2165 0.609 0.164 0.0295 0.0608 0.1155 0.009 0.13 0.105 0.144 0.123 0.153 0.0741 0.136 0.0988 0.413 0.136 0.0924 0.106 0.0876 0.105 0.115 0.063 0.086 0.114 0.231 0.181 0.0316 0.249 0.152 OG 502 181 698 956 361 636 787 1590 317 802 61.6 46.8 72.3 26.1 19.4 79.6 107.4 34.1 40.4 46.6 244 107 19.6 71 160 265 218 35.3 43.7 21.9 50.8 32.6 56.8 68.5 20.2 97.1 139 59.5 13.6 10.6 12.2 14 26.5 171 25.6 23.6 16.3 35.2 24.4 24.9 49 67.7 19.8 26.3 37.7 22.7 1.7 41.2 37.7 14 3270 4050 3180 8860 886 5380 LG 82.4 22.8 45.4 168 137 443 109 151 48 128 12.9 86.2 54.8 10.5 7.23 36.1 78.85 21.1 53.6 35.6 258 71.3 16.1 36.6 249 309 113 13.6 10.6 7.33 17.7 0.803 29.2 22.2 17.1 7.84 68.05 21.7 6.68 3.99 1.59 6.99 6.28 20.4 7.18 10.2 4.34 9.44 6.27 6.24 8.24 20.1 3.27 17.1 4.88 5.64 107 7.78 5.59 7.32 540 727 820 1340 160 727 AG 0.869 2.2 1.45 1.52 10.7 35.1 2.49 4.53 1.85 2.21 1.42 1.56 3.09 1.6 1.32 4.7 6.425 1.53 3.29 2.62 14.7 7.11 2.52 2.89 9.09 19 12.3 0.957 1.79 1.18 1.67 1.49 1.94 2.74 0.584 1.07 4.735 2.18 2.61 1.74 2.93 2.485 2.24 10.4 6.54 1.83 4.14 2.39 2.77 1.63 4.28 11.9 5.85 3.83 4.17 1.36 4.56 4.78 4.71 1.26 19.1 38.5 44.1 63.5 11.4 39.5 MS_METABOLITE_DATA_END #METABOLITES METABOLITES_START metabolite_name PubChem ID KEGG ID Parent Lipid Class HMDB ID InChIKey PEA 4671 C16512 C16:0 Ethanolamide HMDB02100 HXYVTAGFYLMHSO-UHFFFAOYSA-N SEA 27902 C18:0 Ethanolamide HMDB13078 OTGQIQQTPXJQRG-UHFFFAOYSA-N OEA 5283454 C18:1n9 Ethanolamide HMDB02088 BOWVQLFMWHZBEF-KTKRTIGZSA-N LEA 5283446 C18:2n6 Ethanolamide HMDB12252 KQXDGUVSAAQARU-HZJYTTRNSA-N aLEA 5283449 C18:3n3 Ethanolamide HMDB13624 HBJXRRXWHSHZPU-PDBXOOCHSA-N DGLEA 5282272 C13828 C20:3n6 Ethanolamide HMDB13625 ULQWKETUACYZLI-QNEBEIHSSA-N AEA 5281969 C11695 C20:4n6 Ethanolamide HMDB04080 LGEQQWMQCRIYKG-DOFZRALJSA-N DEA 5282273 C13829 C22:4n6 Ethanolamide HMDB13626 FMVHVRYFQIXOAF-DOFZRALJSA-N DHEA 53245830 C22:6n3 Ethanolamide HMDB13627 CXWASNUDKUTFPQ-KUBAVDMBSA-N NO-Gly 6436908 C18:1n9 N-Acyl Glycine HMDB13631 HPFXACZRFJDURI-KTKRTIGZSA-N NA-Gly 5283389 20:4n6 N-Acyl Glycine HMDB05096 YLEARPUNMCCKMP-DOFZRALJSA-N OG Sum (12178130 + 5319879) C18:1n9 1- and 2-Acyl Glycerol Sum (HMDB11567 + HMDB11537) Sum (RZRNAYUHWVFMIP-QJRAZLAKSA-N + UPWGQKDVAURUGE-KTKRTIGZSA-N) LG Sum (6436630 + 5365676) C18:2n6 1- and 2-Acyl Glycerol Sum (HMDB11568 + HMDB11538) Sum (WECGLUPZRHILCT-GSNKCQISSA-N + IEPGNWMPIFDNSD-HZJYTTRNSA-N) AG Sum (16019980 + 5282280) C20:4n6 1- and 2-Acyl Glycerol Sum (HMDB11578 + HMDB04666) Sum (DCPCOKIYJYGMDN-HUDVFFLJSA-N + RCRCTBLIHCHWDZ-DOFZRALJSA-N) METABOLITES_END #END